Discover and read the best of Twitter Threads about #nikhilmunshi
Most recents (3)
Here are my Top 5 #ASH22 @ASH_hematology myeloma abstracts. #ASH22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Not everyone with MGUS diagnosis needs a marrow. Choosing wisely. The iStopMM trial provides a model that limits unnecessary bone marrow biopsies. #ASH22 #ASH22VR @sykristinsson @eliaseythorsson @SaemundurMD @SigrunThorstei1 ash.confex.com/ash/2022/webpr… 
#4 Defining duration of maintenance therapy. Brilliant analysis of Myeloma XI trial. Benefit persists for 3 yrs. But 4-5 yrs after starting maintenance, benefit diminishes. Lot more insights. #ASH22 #ASH22VR @_DrCP @profghjackson @profBigG @DrGarethMorgan1 ash.confex.com/ash/2022/webpr…
There will be a joint FDA/International Myeloma Society workshop on drug development in myeloma. Nov 8-9.
Myeloma has been at the forefront of advances in cancer therapy. Register if interested. Over 1000 have already registered. @US_FDA @Myeloma_Society fda.gov/drugs/news-eve…
Myeloma has been at the forefront of advances in cancer therapy. Register if interested. Over 1000 have already registered. @US_FDA @Myeloma_Society fda.gov/drugs/news-eve…
If you have interest in how we wrestle with competing issues, trial designs, endpoints, and the type of difficult decisions that are made in drug development balancing the needs of the patient, efficacy, safety, etc this workshop will be educational.
The topics discussed will be relevant to all cancers and so those who are in other related fields of oncology will also find the workshop helpful.
Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
